# US 2020/0392086 A1 · (--)-Huperzine A Processes and Related Compositions and Methods of Treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392086 A1
- Document ID: US20200392086A1
- Status: Published application
- Kind: A1
- Application number: 16/892,828
- Filed: 2020-06-04
- Published: 2020-12-17
- Earliest claimed: 2011-03-04
- Assignees: Yale University
- Applicants: Yale University
- Inventors: Seth Herzon; Maung Kyaw Moe Tun
- Web page: https://patentgrep.com/patent/US20200392086A1

## CPC

- C07D 221/22: Bridged ring systems
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07F 7/10: containing nitrogen {having a Si-N linkage}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The invention provides (1) processes for making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; (2) compositions useful in making substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (−) huperzine A and substantially-pure (−) huperzine A derivatives.

## Claims

### Claim at position 1

1-3. (canceled)

### Claim at position 2

4-7. (canceled)

### Claim 8

A process of making an olefination product which is in substantially E isomer form and which has the formula:
comprising deprotonating an addition alkylation product of the formula:
by reacting the addition alkylation product with lithium bis(trimethylsilyl) amide (LHMDS) or lithium diisopropyl amide (LDA) and an electrophilic source of cyanide (e.g., para-toluenesulfonyl cyanide or cyanogen bromide) an organic solvent to form an α-cyanoketone, subjecting the α-cyanoketone to palladium-catalyzed intramolecular enolate heteroarylation in the presence of a base and a palladium catalyst (e.g., tetrakis(triphenylphosphine)palladium or tris(dibenzylidene acetone) dipalladium, palladium bis(tri-tert-butylphoshpine) to form a cyclized product, and stereoselectively olefinating a ketone function of the cyclized product in a Wittig olefination reaction in the presence of a base and in an organic solvent to form an olefination product, wherein the stereoselective olefination of the cyclized product kinetically favors formation of the olefination product in E-isomer form, wherein the process is conducted one-pot or in steps.

### Claim 9 (depends on 8)

The process of claim 8, wherein the addition alkylation product is reacted in a solvent selected from the group consisting of TILT or toluene, the palladium-catalyzed intramolecular enolate heteroarylation base is sodium tert-butoxide, the Wittig olefination reaction base is selected from the group consisting of n-butyllithium, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide or lithium diisopropylamide, and the Wittig olefination reaction organic solvent is selected from the group consisting of THF, diethylether or 1,4-dioxane.

### Claim 10

(canceled)

### Claim 11

A process for making substantially pure (−) huperzine A comprising:
(a) in one pot, reacting (R)-4-methyl-cyclohex-2-ene-1-one with lithium dimethylphenylsilylcuprate in a conjugate addition reaction to form an incipient enolate and alkylating the incipient enolate with 3-bromo-2-(bromomethyl)-6-methoxypyridine) to form an addition alkylation product having the formula:
(b) in one pot, deprotonating the addition alkylation product by reacting the addition alkylation product with lithium bis(trimethylsilyl) amide (LHMDS) or lithium diisopropyl amide (LDA) in an organic solvent to form an α-cyanoketone, subjecting the α-cyanoketone to palladium-catalyzed intramolecular enolate heteroarylation in the presence of a base to form a cyclized product, and stereoselectively olefinating a ketone function of the cyclized product in a Wittig olefination reaction in the presence of a base and in an organic solvent to form an olefination product, wherein the stereoselective olefination of the cyclized product kinetically favors formation of the olefination product in E-isomer form and wherein the olefination product has the formula:
(c) subjecting the olefination product to oxidative disilylation by (1) reaction with a boron trifluoride-acetic acid complex or a Bronsted acid in an inert solvent, or (2) through use of Fleming-Tamao oxidation to form a cyanoalcohol having the formula:
(d) in one pot, dehydrating the cyanoalcohol in an organic solvent under heated conditions and in the presence of a Burgess reagent to form a dehydration product, and subjecting the dehydration product to thermolysis in an alcohol and in the presence of a platinum catalyst to form the amide having the formula:
and
(f) subjecting the amide to modified Hoffmann reaction in an aqueous or alcohol solvent and in the presence of bis(trifluoroacetoxyiodo)benzene (PIFA) to form an intermediate, globally deprotecting the intermediate to form (−) huperzine A, and optionally, further purifying the (−) huperzine A to yield substantially pure (−) huperzine A having the formula:

### Claim 12 (depends on 11)

The process of claim 11, wherein:
(a) the addition alkylation product is reacted with lithium bis(trimethylsilyl) amide (LHMDS) or lithium diisopropyl amide (LDA) in THF or toluene;
(b) the palladium-catalyzed intramolecular enolate heteroarylation base is sodium tert-butoxide;
(c) the Wittig olefination reaction base is selected from the group consisting of n-butyllithium, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide and lithium diisopropylamide; and the Wittig olefination reaction organic solvent is selected from the group consisting of THF, diethylether or 1,4-dioxane;
(d) the oxidative disilylation Bronsted acid is selected from the group consisting of TFA, MSA, FMSA, or tetrafluoroboric acid;
(e) the oxidative disilylation inert solvent is DCM;
(f) the cyanoalcohol dehydration organic solvent is toluene;
(g) the thermolysis alcohol is aqueous ethanol;
(h) the modified Hoffmann reaction alcohol solvent is methanol; and
(i) the (±) huperzine A is purified by flash column chromatography.

### Claim at position 8

13-35. (canceled)

### Claim 36

A compound of the formula (VIII):
wherein:
R1 is selected from the group consisting of substituted or unsubstituted C1-C6 alkyl and substituted or unsubstituted ether;
R2 and R5 are independently selected from the group consisting of H and substituted or unsubstituted C1-C6 alkyl;
R3 at each occurrence is independently selected from the group consisting of H, substituted or unsubstituted C1-C6 alkyl, ether, amino, and alkoxy;
A is C, N, or S; and
n is 0 or 1;
or a pharmaceutically acceptable salt, enantiomer, diastereomer solvate or polymorph thereof.

### Claim 37 (depends on 36)

A compound of claim 36, or a pharmaceutically acceptable salt, enantiomer, diastereomer solvate or polymorph thereof, wherein the compound is:

### Claim at position 11

38-44. (canceled)
